glp-1 drugs stocks Obesity drug stocks: Where to invest now Novo Nordisk Surges 7.3% as
Description
The evidence reveals significant heterogeneity in the effects of GLP-1RAs across different cancer types
However, subsequent clinical trials reported high rates of nausea and vomiting, leading to the perception that PYY-based therapies were intrinsically intolerable
Those who cannot tolerate GLP-1 medications
2016;310:F123F127
Biochem Biophys Res Commun (2019) 516(1):3006
While this single case cannot establish a pattern, it raises questions about whether compounded formulations might carry different risk profiles due to variations in purity, concentration, or additional ingredients
